NVAX vs. TWST, IOVA, DNLI, RLAY, ADPT, EXAS, RGEN, EXEL, HALO, and IONS
Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Twist Bioscience (TWST), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Exact Sciences (EXAS), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Novavax (NASDAQ:NVAX) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk.
Novavax has a net margin of -40.01% compared to Twist Bioscience's net margin of -69.24%. Novavax's return on equity of 0.00% beat Twist Bioscience's return on equity.
Novavax currently has a consensus price target of $17.50, suggesting a potential upside of 16.43%. Twist Bioscience has a consensus price target of $42.50, suggesting a potential upside of 1.43%. Given Novavax's higher probable upside, analysts plainly believe Novavax is more favorable than Twist Bioscience.
Novavax has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.
Novavax received 754 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.14% of users gave Novavax an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
In the previous week, Novavax had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 6 mentions for Novavax and 5 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.21 beat Novavax's score of 0.66 indicating that Twist Bioscience is being referred to more favorably in the news media.
53.0% of Novavax shares are owned by institutional investors. 0.9% of Novavax shares are owned by company insiders. Comparatively, 3.9% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Twist Bioscience has lower revenue, but higher earnings than Novavax. Twist Bioscience is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Summary
Novavax beats Twist Bioscience on 11 of the 18 factors compared between the two stocks.
Get Novavax News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
